{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:06:50Z","timestamp":1792026410486,"version":"4.4.0"},"reference-count":241,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01525"],"award-info":[{"award-number":["PI22\/01525"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Medical treatment of hypercortisolism may be necessary for a high proportion of patients with Cushing syndrome (CS), including those who are not candidates for curative surgery. It may also be used in the presurgical period when hypercortisolism is severe, as long-term treatment following surgical failure or recurrence after surgery, or while waiting for the effects of pituitary radiation in Cushing disease. Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In addition, there are other medical treatments in development that target pituitary signaling pathways, ACTH or its adrenal receptor, or the conversion of cortisol from cortisone by 11\u00dfHSD1. Steroidogenesis inhibitors can be administered using either a titration or a block-and-replace approach. Titration requires adjusting the daily drug dose with the aim of normalizing circulating cortisol levels, whereas the block-and-replace strategy uses higher drug doses to fully suppress endogenous cortisol production, followed by glucocorticoid supplementation. In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS, and mild autonomous cortisol secretion.<\/jats:p>","DOI":"10.1210\/endrev\/bnaf042","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:11:01Z","timestamp":1765545061000},"page":"301-328","source":"Crossref","is-referenced-by-count":17,"title":["Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome"],"prefix":"10.1210","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[{"name":"Endocrinology & Nutrition Department, Ram\u00f3n y Cajal Hospital , 28034 Madrid ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica Ram\u00f3n y Cajal (IRYCIS) , 28034 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-9508","authenticated-orcid":false,"given":"Cristina","family":"Lamas","sequence":"additional","affiliation":[{"name":"Endocrinology & Nutrition Department, Complejo Hospitalario Universitario de Albacete , 02006 Albacete ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7323-9085","authenticated-orcid":false,"given":"Elisabeth","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich , 81377 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-5493","authenticated-orcid":false,"given":"John","family":"Newell-Price","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield , Sheffield S10 T2N ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9875","authenticated-orcid":false,"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU University Hospital, LMU Munich , 81377 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield , Sheffield S10 T2N ,","place":["UK"]},{"name":"Aix Marseille Univ, INSERM U1251, Marseille Medical Genetics , 13005 Marseille ,","place":["France"]},{"name":"Assistance Publique H\u00f4pitaux de Marseille, Hopital La Conception , 13005 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"8","key":"2026051219561531200_bnaf042-B1","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026051219561531200_bnaf042-B2","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","article-title":"Epidemiology and mortality of Cushing's syndrome","volume":"35","author":"Hakami","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B3","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing's syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"5","key":"2026051219561531200_bnaf042-B4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11102-020-01066-8","article-title":"Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis","volume":"23","author":"Stroud","year":"2020","journal-title":"Pituitary"},{"issue":"12","key":"2026051219561531200_bnaf042-B5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2026051219561531200_bnaf042-B6","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026051219561531200_bnaf042-B7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11102-018-0894-2","article-title":"Two types of ectopic Cushing syndrome or a continuum? Review","volume":"21","author":"Araujo Castro","year":"2018","journal-title":"Pituitary"},{"key":"2026051219561531200_bnaf042-B8","doi-asserted-by":"crossref","first-page":"1060884","DOI":"10.3389\/fendo.2022.1060884","article-title":"Individualized medical treatment options in Cushing disease","volume":"13","author":"Gilis-Januszewska","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026051219561531200_bnaf042-B9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: a review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"2026051219561531200_bnaf042-B10","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1210\/jc.2019-00333","article-title":"Why we should still treat by neurosurgery patients with Cushing disease and a normal or inconclusive pituitary MRI","volume":"104","author":"Cristante","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ando.2022.02.001","article-title":"Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome","volume":"83","author":"Tabarin","year":"2022","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2026051219561531200_bnaf042-B12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12020-025-04304-w","article-title":"Prediction of remission and recurrence of Cushing's disease following transsphenoidal surgery (TSS): a single center, 20-year, retrospective series","volume":"90","author":"Natan","year":"2025","journal-title":"Endocrine"},{"issue":"3","key":"2026051219561531200_bnaf042-B13","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1093\/ejendo\/lvae110","article-title":"How to manage Cushing's disease after failed primary pituitary surgery","volume":"191","author":"Agrawal","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026051219561531200_bnaf042-B14","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.21037\/apm-20-2230","article-title":"Treatment and outcomes of recurrent\/persistent Cushing's disease: a single-center experience","volume":"10","author":"Liu","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"4","key":"2026051219561531200_bnaf042-B15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2265.2011.04268.x","article-title":"Contemporary microsurgical concept for the treatment of Cushing's disease: endocrine outcome in 83 consecutive patients","volume":"76","author":"Honegger","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026051219561531200_bnaf042-B16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","article-title":"An individualized approach to the management of Cushing disease","volume":"19","author":"Fleseriu","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2026051219561531200_bnaf042-B17","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1210\/jc.2013-1470","article-title":"Clinical review: outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review","volume":"98","author":"Ritzel","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026051219561531200_bnaf042-B18","doi-asserted-by":"crossref","first-page":"D9","DOI":"10.1530\/EJE-19-0092","article-title":"Radiotherapy as a tool for the treatment of Cushing's disease","volume":"180","author":"Castinetti","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026051219561531200_bnaf042-B19","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026051219561531200_bnaf042-B20","doi-asserted-by":"crossref","first-page":"102908","DOI":"10.1016\/j.arcmed.2023.102908","article-title":"Pharmacological treatment of Cushing's syndrome","volume":"54","author":"Castinetti","year":"2023","journal-title":"Arch Med Res"},{"issue":"6","key":"2026051219561531200_bnaf042-B21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.surg.2008.08.024","article-title":"Waiting for change: symptom resolution after adrenalectomy for Cushing's syndrome","volume":"144","author":"Sippel","year":"2008","journal-title":"Surgery"},{"issue":"4","key":"2026051219561531200_bnaf042-B22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-17-0997","article-title":"Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN","volume":"178","author":"Valassi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026051219561531200_bnaf042-B23","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026051219561531200_bnaf042-B24","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/ERC-15-0541","article-title":"Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?","volume":"23","author":"Guerin","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2026051219561531200_bnaf042-B25","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenick\u00fd","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B27","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tem.2023.12.003","article-title":"A clinical perspective on ectopic Cushing's syndrome","volume":"35","author":"Ragnarsson","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2026051219561531200_bnaf042-B29","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026051219561531200_bnaf042-B30","doi-asserted-by":"crossref","first-page":"101376","DOI":"10.1016\/j.beem.2020.101376","article-title":"What is the role of medical therapy in adrenal-dependent Cushing's syndrome?","volume":"34","author":"Braun","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B31","first-page":"229","article-title":"Primary bilateral macronodular adrenal hyperplasia: a series of 32 cases and literature review","volume":"70","author":"Araujo-Castro","year":"2023","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"5","key":"2026051219561531200_bnaf042-B32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00268-007-9408-5","article-title":"The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH)","volume":"32","author":"Iacobone","year":"2008","journal-title":"World J Surg"},{"issue":"12","key":"2026051219561531200_bnaf042-B33","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1210\/jc.2015-2662","article-title":"Unilateral adrenalectomy as a first-line treatment of Cushing's syndrome in patients with primary bilateral macronodular adrenal hyperplasia","volume":"100","author":"Debillon","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026051219561531200_bnaf042-B34","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1210\/jc.2018-02204","article-title":"Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy","volume":"104","author":"Osswald","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026051219561531200_bnaf042-B35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1530\/EJE-15-0566","article-title":"Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas","volume":"173","author":"Perogamvros","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026051219561531200_bnaf042-B36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/oncolo\/oyae084","article-title":"A review of mitotane in the management of adrenocortical cancer","volume":"29","author":"Del Rivero","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"2026051219561531200_bnaf042-B37","doi-asserted-by":"crossref","first-page":"e250034","DOI":"10.1530\/ERC-25-0034","article-title":"Spanish consensus on the diagnosis and management of adrenocortical carcinoma","volume":"32","author":"Araujo-Castro","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026051219561531200_bnaf042-B38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B39","doi-asserted-by":"crossref","first-page":"1017331","DOI":"10.3389\/fendo.2022.1017331","article-title":"Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort","volume":"13","author":"Viecceli","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2026051219561531200_bnaf042-B40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2026051219561531200_bnaf042-B42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","article-title":"Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026051219561531200_bnaf042-B43","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026051219561531200_bnaf042-B44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing's syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2026051219561531200_bnaf042-B45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ejendo\/lvaf181","article-title":"Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT)","volume":"193","author":"Nieman","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026051219561531200_bnaf042-B46","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026051219561531200_bnaf042-B47","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026051219561531200_bnaf042-B49","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2026051219561531200_bnaf042-B50","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/cen.14081","article-title":"Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: a phase III extension study","volume":"91","author":"Fleseriu","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026051219561531200_bnaf042-B51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing's disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B52","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026051219561531200_bnaf042-B53","doi-asserted-by":"crossref","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","article-title":"Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome\u2014a practical guide","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B54","doi-asserted-by":"crossref","first-page":"1145775","DOI":"10.3389\/fendo.2023.1145775","article-title":"Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis","volume":"14","author":"Viecceli","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026051219561531200_bnaf042-B55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"issue":"1","key":"2026051219561531200_bnaf042-B56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2012.12.015","article-title":"The medical management of Cushing's syndrome during pregnancy","volume":"168","author":"Lim","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"2026051219561531200_bnaf042-B57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-0031-1293542","article-title":"Management of pituitary tumors in pregnancy","volume":"31","author":"Iuliano","year":"2011","journal-title":"Semin Neurol"},{"issue":"6","key":"2026051219561531200_bnaf042-B58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","article-title":"Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"issue":"5","key":"2026051219561531200_bnaf042-B59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026051219561531200_bnaf042-B60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14656566.2023.2192349","article-title":"An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options?","volume":"24","author":"Martino","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"2026051219561531200_bnaf042-B61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/17446651.2021.1945440","article-title":"Levoketoconazole: a novel treatment for endogenous Cushing's syndrome","volume":"16","author":"Fleseriu","year":"2021","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B62","doi-asserted-by":"crossref","first-page":"595894","DOI":"10.3389\/fendo.2021.595894","article-title":"Levoketoconazole in the treatment of patients with Cushing's syndrome and diabetes mellitus: results from the SONICS phase 3 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement_1","key":"2026051219561531200_bnaf042-B63","doi-asserted-by":"crossref","first-page":"bvae163.1357","DOI":"10.1210\/jendso\/bvae163.1357","article-title":"6570 treatment of Cushing's with levoketoconazole: a case series","volume":"8","author":"Chamorro-Pareja","year":"2024","journal-title":"J Endocr Soc"},{"issue":"4","key":"2026051219561531200_bnaf042-B64","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B65","doi-asserted-by":"crossref","first-page":"903545","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing's syndrome: results from a Single Center Cohort Study","volume":"13","author":"Detomas","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026051219561531200_bnaf042-B66","doi-asserted-by":"crossref","first-page":"1511155","DOI":"10.3389\/fendo.2024.1511155","article-title":"Metyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing's syndrome","volume":"15","author":"Tsujimoto","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026051219561531200_bnaf042-B67","first-page":"103","article-title":"Successful use of metyrapone suppositories in an infant with neonatal Cushing and McCune Albright Syndrome\u2014a case report","volume":"98","author":"Ertl","year":"2023","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"2026051219561531200_bnaf042-B68","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051219561531200_bnaf042-B69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-22-0208","article-title":"Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients","volume":"187","author":"Bonnet-Serrano","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026051219561531200_bnaf042-B70","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"2026051219561531200_bnaf042-B71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026051219561531200_bnaf042-B72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11102-025-01525-0","article-title":"Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"2026051219561531200_bnaf042-B73","doi-asserted-by":"crossref","first-page":"bvae201","DOI":"10.1210\/jendso\/bvae201","article-title":"Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol","volume":"9","author":"Newell-Price","year":"2024","journal-title":"J Endocr Soc"},{"issue":"2","key":"2026051219561531200_bnaf042-B74","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026051219561531200_bnaf042-B75","doi-asserted-by":"crossref","first-page":"bvaf046","DOI":"10.1210\/jendso\/bvaf046","article-title":"Osilodrostat treatment of Cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study","volume":"9","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"issue":"12","key":"2026051219561531200_bnaf042-B76","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/ml400324c","article-title":"Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors","volume":"4","author":"Meredith","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2026051219561531200_bnaf042-B77","first-page":"43","article-title":"Osilodrostat: a novel potent inhibitor of 11-beta-hydroxylase for the treatment of Cushing's syndrome","volume":"20","author":"Pivonello","year":"2024","journal-title":"TouchREVIEWS Endocrinol"},{"issue":"12","key":"2026051219561531200_bnaf042-B78","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/clinem\/dgaf206","article-title":"Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing's syndrome","volume":"110","author":"Ferrari","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026051219561531200_bnaf042-B79","doi-asserted-by":"crossref","first-page":"506\u2013","DOI":"10.1093\/ejendo\/lvaf207","article-title":"Osilodrostat dose impact on efficacy\/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4","volume":"193","author":"Fleseriu","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026051219561531200_bnaf042-B80","doi-asserted-by":"crossref","first-page":"K11","DOI":"10.1093\/ejendo\/lvaf185","article-title":"A preliminary model to tailor osilodrostat in patients with adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome","volume":"193","author":"Piazzola","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026051219561531200_bnaf042-B81","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAF552","article-title":"Osilodrostat-associated adrenal gland shrinkage: a case series of patients with ACTH-dependent Cushing's syndrome","author":"Varlamov","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051219561531200_bnaf042-B82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0039-128X(93)90054-Q","article-title":"Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells","volume":"58","author":"Varga","year":"1993","journal-title":"Steroids"},{"issue":"2","key":"2026051219561531200_bnaf042-B83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","article-title":"Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026051219561531200_bnaf042-B84","doi-asserted-by":"crossref","first-page":"bvaf039","DOI":"10.1210\/jendso\/bvaf039","article-title":"Etomidate in severe Cushing syndrome: a systematic review","volume":"9","author":"Muthukuda","year":"2025","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026051219561531200_bnaf042-B85","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects","volume":"70","author":"Schulte","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026051219561531200_bnaf042-B86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/js.2018-00269","article-title":"Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol","volume":"3","author":"Carroll","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026051219561531200_bnaf042-B87","doi-asserted-by":"crossref","first-page":"20420188211058583","DOI":"10.1177\/20420188211058583","article-title":"Pharmacological management of severe Cushing's syndrome: the role of etomidate","volume":"13","author":"Pence","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"2026051219561531200_bnaf042-B88","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0272-6386(97)90577-1","article-title":"Propylene glycol-induced proximal renal tubular cell injury","volume":"30","author":"Yorgin","year":"1997","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2026051219561531200_bnaf042-B89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ecl.2020.05.003","article-title":"Advances in the medical treatment of Cushing disease","volume":"49","author":"Tritos","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2026051219561531200_bnaf042-B90","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2026051219561531200_bnaf042-B91","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/ERC-22-0088","article-title":"Improved pasireotide response in USP8 mutant corticotroph tumours in vitro","volume":"29","author":"Albani","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026051219561531200_bnaf042-B92","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026051219561531200_bnaf042-B93","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2026051219561531200_bnaf042-B94","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","article-title":"Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study","volume":"43","author":"Lacroix","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"2026051219561531200_bnaf042-B95","doi-asserted-by":"crossref","first-page":"1165681","DOI":"10.3389\/fendo.2023.1165681","article-title":"Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease","volume":"14","author":"Feelders","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026051219561531200_bnaf042-B96","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial","volume":"57","author":"Petersenn","year":"2017","journal-title":"Endocrine"},{"issue":"7","key":"2026051219561531200_bnaf042-B97","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2174\/0118715303260160231020070423","article-title":"Case report: opposite tumoral and hormonal responses to low-dose pasireotide in Cushing's disease","volume":"24","author":"Serban","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2026051219561531200_bnaf042-B98","doi-asserted-by":"crossref","first-page":"20-0206","DOI":"10.1530\/EDM-20-0206","article-title":"Cushing's disease: does low-dose pasireotide offer a comparable efficacy and safety to high-dose?","volume":"2021","author":"Wong","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Reports"},{"key":"2026051219561531200_bnaf042-B99","doi-asserted-by":"crossref","first-page":"1250822","DOI":"10.3389\/fendo.2024.1250822","article-title":"Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study","volume":"15","author":"Feldt-Rasmussen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026051219561531200_bnaf042-B100","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026051219561531200_bnaf042-B101","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","article-title":"The dopaminergic control of Cushing's syndrome","volume":"45","author":"Pivonello","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026051219561531200_bnaf042-B102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026051219561531200_bnaf042-B103","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing's disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026051219561531200_bnaf042-B104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.14310\/horm.2002.1685","article-title":"Cabergoline treatment for recurrent Cushing's disease during pregnancy","volume":"15","author":"Nakhleh","year":"2016","journal-title":"Hormones (Athens)"},{"key":"2026051219561531200_bnaf042-B105","first-page":"485\u2013","article-title":"Cabergoline therapy for Cushing disease throughout pregnancy","volume":"122","author":"Woo","year":"2013","journal-title":"Pharm Res Am J Obs Gynecol"},{"issue":"1","key":"2026051219561531200_bnaf042-B106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40842-020-00105-4","article-title":"Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations","volume":"6","author":"Brown","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"issue":"5","key":"2026051219561531200_bnaf042-B107","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-2952(96)00357-7","article-title":"Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes","volume":"52","author":"Jang","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"2026051219561531200_bnaf042-B108","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/cen.12332","article-title":"Global clinical response in Cushing's syndrome patients treated with mifepristone","volume":"80","author":"Katznelson","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026051219561531200_bnaf042-B109","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026051219561531200_bnaf042-B110","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1210\/jc.2018-02638","article-title":"Mifepristone treatment in four cases of primary bilateral macronodular adrenal hyperplasia (BMAH)","volume":"104","author":"Cohan","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026051219561531200_bnaf042-B111","doi-asserted-by":"crossref","first-page":"e081121","DOI":"10.1136\/bmjopen-2023-081121","article-title":"Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone","volume":"14","author":"DeFronzo","year":"2024","journal-title":"BMJ Open"},{"issue":"5","key":"2026051219561531200_bnaf042-B112","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/cen.13818","article-title":"Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome","volume":"89","author":"Wannachalee","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026051219561531200_bnaf042-B113","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.4158\/EP11391.CR","article-title":"Successful long-term treatment of Cushing disease with mifepristone (RU486)","volume":"18","author":"Basina","year":"2012","journal-title":"Endocr Pract"},{"issue":"10","key":"2026051219561531200_bnaf042-B114","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4158\/EP15760.OR","article-title":"Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome","volume":"21","author":"Yuen","year":"2015","journal-title":"Endocr Pract"},{"issue":"3","key":"2026051219561531200_bnaf042-B115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/phar.1202","article-title":"Mifepristone for management of Cushing's syndrome","volume":"33","author":"Morgan","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2026051219561531200_bnaf042-B116","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome","volume":"77","author":"Valassi","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026051219561531200_bnaf042-B117","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"issue":"2","key":"2026051219561531200_bnaf042-B118","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"2026051219561531200_bnaf042-B119","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s42000-022-00397-4","article-title":"Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia","volume":"21","author":"Dzialach","year":"2022","journal-title":"Hormones"},{"issue":"19","key":"2026051219561531200_bnaf042-B120","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"issue":"5463","key":"2026051219561531200_bnaf042-B121","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"2026051219561531200_bnaf042-B122","article-title":"Prospective phase II study (capacity) of pasireotide monotherapy or in combination with cabergoline in patients with Cushing's disease","volume":"38","author":"Feelders","year":"2017","journal-title":"Endocr Rev"},{"key":"2026051219561531200_bnaf042-B123","doi-asserted-by":"crossref","first-page":"BVAF089","DOI":"10.1210\/jendso\/bvaf089","article-title":"A prospective trial with ketoconazole induction therapy and octreotide maintenance treatment for Cushing's disease","volume":"9","author":"Paes","year":"2025","journal-title":"J Endocr Soc"},{"issue":"8","key":"2026051219561531200_bnaf042-B124","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1021\/acs.jmedchem.7b00162","article-title":"Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective glucocorticoid receptor (GR) antagonist","volume":"60","author":"Hunt","year":"2017","journal-title":"J Med Chem"},{"key":"2026051219561531200_bnaf042-B125","doi-asserted-by":"crossref","first-page":"662865","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement_1","key":"2026051219561531200_bnaf042-B126","doi-asserted-by":"crossref","first-page":"bvae163.1287","DOI":"10.1210\/jendso\/bvae163.1287","article-title":"9323 Open-label results from grace, a phase 3 double-blind, randomized-withdrawal study of the selective glucocorticoid receptor modulator relacorilant for the treatment of endogenous hypercortisolism (Cushing syndrome)","volume":"8","author":"Pivonello","year":"2024","journal-title":"J Endocr Soc"},{"issue":"7","key":"2026051219561531200_bnaf042-B127","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","article-title":"Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease","volume":"100","author":"Liu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026051219561531200_bnaf042-B128","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of Cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"2026051219561531200_bnaf042-B129","doi-asserted-by":"crossref","first-page":"bvae163.114","DOI":"10.1210\/jendso\/bvae163.114","article-title":"9330 Atumelnant (crn04894) induces rapid and sustained reductions in serum and urine cortisol in patients with acth-dependent Cushing syndrome during a phase 1b\/2a, single center, 10-day, inpatient, open-label study","volume":"8","author":"Elenius","year":"2024","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026051219561531200_bnaf042-B130","first-page":"57","article-title":"Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion","volume":"87","author":"Tomlinson","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026051219561531200_bnaf042-B131","doi-asserted-by":"crossref","first-page":"101701","DOI":"10.1016\/j.beem.2022.101701","article-title":"Innovative tumour targeting therapeutics in Cushing's disease","volume":"36","author":"von Selzam","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"2026051219561531200_bnaf042-B132","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1530\/ERC-21-0093","article-title":"USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs","volume":"28","author":"Treppiedi","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026051219561531200_bnaf042-B133","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","article-title":"Identification of recurrent USP48 and BRAF mutations in Cushing's disease","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"2026051219561531200_bnaf042-B134","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/EJE-18-0062","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: can we cure Cushing's disease? A personal view","volume":"178","author":"Bertagna","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026051219561531200_bnaf042-B135","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-20-0352","article-title":"ENDOCRINOLOGY IN THE TIME OF COVID-19: management of Cushing's syndrome","volume":"183","author":"Newell-Price","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026051219561531200_bnaf042-B136","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026051219561531200_bnaf042-B137","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/jcph.326","article-title":"Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study","volume":"54","author":"Petersenn","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2026051219561531200_bnaf042-B138","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.1993.tb02391.x","article-title":"The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome","volume":"39","author":"Trainer","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026051219561531200_bnaf042-B139","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/EJE-19-0695","article-title":"Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease","volume":"182","author":"Newell-Price","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026051219561531200_bnaf042-B140","doi-asserted-by":"crossref","first-page":"e13120","DOI":"10.1111\/jne.13120","article-title":"Medical management of Cushing's disease: when and how?","volume":"34","author":"Castinetti","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"2026051219561531200_bnaf042-B141","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"2026051219561531200_bnaf042-B142","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for Cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026051219561531200_bnaf042-B143","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1210\/clinem\/dgad251","article-title":"Evidence of persistent mild hypercortisolism in patients medically treated for Cushing disease: the Haircush Study","volume":"108","author":"Mohammedi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051219561531200_bnaf042-B144","doi-asserted-by":"crossref","first-page":"EVIDOA2200182","DOI":"10.1056\/EVIDoa2200182","article-title":"Home waking salivary cortisone to screen for adrenal insufficiency","volume":"2","author":"Debono","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"2026051219561531200_bnaf042-B145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026051219561531200_bnaf042-B146","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-8587(23)00150-X","article-title":"Diagnostic challenges in cyclic Cushing's syndrome: a systematic review","volume":"11","author":"Nowak","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026051219561531200_bnaf042-B147","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1530\/EJE-07-0262","article-title":"Cyclic Cushing's syndrome: a clinical challenge","volume":"157","author":"Meinardi","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B148","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1530\/EJE-09-0046","article-title":"The prevalence and characteristic features of cyclicity and variability in Cushing's disease","volume":"160","author":"Alexandraki","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026051219561531200_bnaf042-B149","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S2213-8587(25)00249-9","article-title":"Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study","volume":"13","author":"Nowak","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B150","doi-asserted-by":"crossref","first-page":"R259","DOI":"10.1530\/EJE-17-1058","article-title":"Management of Cushing's syndrome during pregnancy: solved and unsolved questions","volume":"178","author":"Brue","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"25","key":"2026051219561531200_bnaf042-B151","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1080\/14767058.2021.1910658","article-title":"The effect of Cushing's syndrome on pregnancy complication rates: analysis of more than 9 million deliveries","volume":"35","author":"Baghlaf","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"2","key":"2026051219561531200_bnaf042-B152","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12020-016-1117-0","article-title":"Cushing's syndrome and pregnancy outcomes: a systematic review of published cases","volume":"55","author":"Caimari","year":"2017","journal-title":"Endocrine"},{"issue":"3","key":"2026051219561531200_bnaf042-B153","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ecl.2024.05.007","article-title":"Conundrums of diagnosis and management of Cushing's syndrome in pregnancy","volume":"53","author":"Livia Gheorghiu","year":"2024","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2026051219561531200_bnaf042-B154","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11154-022-09731-y","article-title":"Endogenous Cushing's syndrome during pregnancy","volume":"24","author":"Younes","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"2026051219561531200_bnaf042-B155","doi-asserted-by":"crossref","first-page":"e13118","DOI":"10.1111\/jne.13118","article-title":"The diagnosis and management of Cushing's syndrome in pregnancy","volume":"34","author":"Hamblin","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026051219561531200_bnaf042-B156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvaa167","article-title":"Adrenal Cushing syndrome diagnosed during pregnancy: successful medical management with metyrapone","volume":"5","author":"Azzola","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026051219561531200_bnaf042-B157","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1479-828X.2011.01388.x","article-title":"Pregnancy-induced Cushing's syndrome in recurrent pregnancies: case report and literature review","volume":"52","author":"Achong","year":"2012","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"9","key":"2026051219561531200_bnaf042-B158","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3109\/09513590.2010.521268","article-title":"Successful outcome of pregnancy in a patient with Cushing's disease under treatment with ketoconazole during the first trimester of gestation","volume":"27","author":"Boronat","year":"2011","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2026051219561531200_bnaf042-B159","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF03344091","article-title":"Cushing's syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy","volume":"29","author":"Blanco","year":"2006","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2026051219561531200_bnaf042-B160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.aace.2021.10.004","article-title":"Cushing disease treated successfully with metyrapone during pregnancy","volume":"8","author":"Bass","year":"2022","journal-title":"AACE Clin Case Reports"},{"issue":"6","key":"2026051219561531200_bnaf042-B161","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/iju5.12637","article-title":"Cushing's syndrome in pregnancy in which laparoscopic adrenalectomy was safely performed by a retroperitoneal approach","volume":"6","author":"Takeuchi","year":"2023","journal-title":"IJU Case Rep"},{"issue":"2","key":"2026051219561531200_bnaf042-B162","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2265.2001.01055.x","article-title":"Recurrent ACTH-independent Cushing's syndrome in multiple pregnancies and its treatment with metyrapone","volume":"54","author":"H\u00e1na","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026051219561531200_bnaf042-B163","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/09513590.2017.1290070","article-title":"A successful case of pregnancy in a woman with ACTH-independent Cushing's syndrome treated with ketoconazole and metyrapone","volume":"33","author":"Zieleniewski","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"773","key":"2026051219561531200_bnaf042-B164","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/pgmj.66.773.221","article-title":"Successful treatment with ketoconazole of Cushing's syndrome in pregnancy","volume":"66","author":"Amadol","year":"1990","journal-title":"Postgrad Med J"},{"issue":"3","key":"2026051219561531200_bnaf042-B165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/09513599909167552","article-title":"Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature","volume":"13","author":"Berwaerts","year":"1999","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2026051219561531200_bnaf042-B166","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/AOG.0b013e31829e398a","article-title":"Cabergoline therapy for Cushing disease throughout pregnancy","volume":"122","author":"Woo","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2026051219561531200_bnaf042-B167","doi-asserted-by":"crossref","first-page":"bcr-2016-217855","DOI":"10.1136\/bcr-2016-217855","article-title":"Use of cabergoline for the management of persistent Cushing's disease in pregnancy","volume":"2017","author":"Sek","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2026051219561531200_bnaf042-B168","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/JOE-14-0300","article-title":"Treatment of Cushing's disease: a mechanistic update","volume":"223","author":"Cuevas-Ramos","year":"2014","journal-title":"J Endocrinol"},{"key":"2026051219561531200_bnaf042-B169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12345","article-title":"Efficacy of medical treatment in Cushing's disease: a systematic review","volume":"80","author":"Gadelha","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2026051219561531200_bnaf042-B170","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-024-00984-y","article-title":"Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches","volume":"20","author":"Prete","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2026051219561531200_bnaf042-B171","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S2213-8587(22)00100-0","article-title":"Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study","volume":"10","author":"Deutschbein","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026051219561531200_bnaf042-B172","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ando.2023.01.005","article-title":"Possible, probable, and certain hypercortisolism: a continuum in the risk of comorbidity","volume":"84","author":"Araujo-Castro","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"2026051219561531200_bnaf042-B173","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2009-2387","article-title":"Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism","volume":"95","author":"Chiodini","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B174","first-page":"991","article-title":"Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome","volume":"152","author":"Iacobone","year":"2012","journal-title":"Surg (United States)"},{"key":"2026051219561531200_bnaf042-B175","doi-asserted-by":"crossref","first-page":"1374711","DOI":"10.3389\/fendo.2024.1374711","article-title":"Comparison of adrenalectomy with conservative treatment on mild autonomous cortisol secretion: a systematic review and meta-analysis","volume":"15","author":"Khadembashiri","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"21","key":"2026051219561531200_bnaf042-B176","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.3390\/ijms222111521","article-title":"Management and medical therapy of mild hypercortisolism","volume":"22","author":"Favero","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026051219561531200_bnaf042-B177","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1210\/jc.2017-00823","article-title":"Resetting the abnormal circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion","volume":"102","author":"Debono","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B178","doi-asserted-by":"crossref","first-page":"140083","DOI":"10.1530\/EDM-14-0083","article-title":"Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia","volume":"2014","author":"Comte-Perret","year":"2014","journal-title":"Endocrinol Diabetes Metab Case Reports"},{"key":"2026051219561531200_bnaf042-B179","doi-asserted-by":"crossref","first-page":"e60984","DOI":"10.1371\/journal.pone.0060984","article-title":"Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study","volume":"8","author":"Debono","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2026051219561531200_bnaf042-B180","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4158\/EP-2019-0047","article-title":"Mifepristone treatment for mild autonomous cortisol secretion due to adrenal adenomas: a pilot study","volume":"25","author":"Belokovskaya","year":"2019","journal-title":"Endocr Pract"},{"key":"2026051219561531200_bnaf042-B181","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.wneu.2024.08.090","article-title":"Venous thromboembolism and prevention strategies in patients with Cushing's disease: a systematic review","volume":"191","author":"White","year":"2024","journal-title":"World Neurosurg"},{"key":"2026051219561531200_bnaf042-B182","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fendo.2018.00805","article-title":"Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing's syndrome: a systematic meta-analysis","volume":"9","author":"Wagner","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026051219561531200_bnaf042-B183","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cen.12094","article-title":"Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment","volume":"78","author":"Van Der Pas","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2026051219561531200_bnaf042-B184","first-page":"3662","article-title":"Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome","volume":"87","author":"Boscaro","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026051219561531200_bnaf042-B185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-022-02320-x","article-title":"Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)","volume":"17","author":"van Haalen","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026051219561531200_bnaf042-B186","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement","volume":"192","author":"Isand","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026051219561531200_bnaf042-B187","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2026051219561531200_bnaf042-B188","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","article-title":"Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"40","author":"Fallo","year":"2022","journal-title":"J Hypertens"},{"issue":"3","key":"2026051219561531200_bnaf042-B189","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026051219561531200_bnaf042-B190","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s40618-025-02572-x","article-title":"Cardiometabolic complications after Cushing's disease remission","volume":"48","author":"Tizianel","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"2026051219561531200_bnaf042-B191","doi-asserted-by":"crossref","first-page":":2595","DOI":"10.1210\/clinem\/dgae904","article-title":"Cushing disease clinical phenotype and tumor behavior vary with age: diagnostic and perioperative implications","volume":"110","author":"Salcedo-Sifuentes","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B192","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ejendo\/lvae127","article-title":"Frequency of clinical signs in patients with Cushing's syndrome and mild autonomous cortisol secretion: overlap is common","volume":"191","author":"Braun","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026051219561531200_bnaf042-B193","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/HJH.0000000000000415","article-title":"The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications","volume":"33","author":"Isidori","year":"2015","journal-title":"J Hypertens"},{"issue":"3","key":"2026051219561531200_bnaf042-B194","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1210\/clinem\/dgad453","article-title":"Long-term consequences of Cushing syndrome: a systematic literature review","volume":"109","author":"Puglisi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B195","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051219561531200_bnaf042-B196","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"issue":"8","key":"2026051219561531200_bnaf042-B197","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B198","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2147\/DMSO.S466328","article-title":"Management of diabetes Mellitus in acromegaly and Cushing's disease with focus on pasireotide therapy: a narrative review","volume":"17","author":"De Fano","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"27","key":"2026051219561531200_bnaf042-B199","doi-asserted-by":"crossref","first-page":"E797","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"CMAJ"},{"key":"2026051219561531200_bnaf042-B200","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s11102-024-01427-7","article-title":"Cushing's disease and bone","volume":"27","author":"Zdrojowy-We\u0142na","year":"2024","journal-title":"Pituitary"},{"issue":"2","key":"2026051219561531200_bnaf042-B201","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12020-023-03318-6","article-title":"Trabecular bone score, bone marrow fat and vertebral fractures in Cushing syndrome","volume":"80","author":"Ferra\u00f9","year":"2023","journal-title":"Endocrine"},{"key":"2026051219561531200_bnaf042-B202","doi-asserted-by":"crossref","first-page":"e13114","DOI":"10.1111\/jne.13114","article-title":"Clinical presentation and etiology of Cushing's syndrome: data from ERCUSYN","volume":"34","author":"Valassi","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2026051219561531200_bnaf042-B203","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","article-title":"Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study","volume":"58","author":"Di Somma","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026051219561531200_bnaf042-B204","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","article-title":"Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants","volume":"25","author":"Trementino","year":"2014","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026051219561531200_bnaf042-B205","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/jc.2011-1661","article-title":"Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study","volume":"96","author":"Stuijver","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051219561531200_bnaf042-B206","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142017 executive summary","volume":"23","author":"Garber","year":"2017","journal-title":"Endocr Pract"},{"key":"2026051219561531200_bnaf042-B207","doi-asserted-by":"crossref","first-page":"e240046","DOI":"10.1530\/EC-24-0046","article-title":"Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey","volume":"13","author":"Cherenko","year":"2024","journal-title":"Endocr Connect"},{"issue":"1","key":"2026051219561531200_bnaf042-B208","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ejendo\/lvad176","article-title":"High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery","volume":"190","author":"Isand","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"S1","key":"2026051219561531200_bnaf042-B209","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40618-024-02454-8","article-title":"Unusual infections and thrombotic events in Cushing's syndrome","volume":"48","author":"Barbot","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026051219561531200_bnaf042-B210","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a Cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B211","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026051219561531200_bnaf042-B212","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41572-024-00588-w","article-title":"Cushing syndrome","volume":"11","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026051219561531200_bnaf042-B213","doi-asserted-by":"crossref","first-page":"1248985","DOI":"10.3389\/fendo.2023.1248985","article-title":"Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours","volume":"14","author":"Guarnotta","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026051219561531200_bnaf042-B214","doi-asserted-by":"crossref","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","article-title":"Osteopathy in mild adrenal Cushing's syndrome and Cushing disease","volume":"35","author":"Frara","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B215","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5114\/reum\/169889","article-title":"Musculoskeletal complications of Cushing syndrome","volume":"61","author":"Leszczy\u0144ska","year":"2023","journal-title":"Reumatologia"},{"issue":"3","key":"2026051219561531200_bnaf042-B216","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.eprac.2024.12.009","article-title":"Bone mineral density improvement after resolution of endogenous Cushing syndrome: a systematic review and meta-analysis","volume":"31","author":"Charoenngam","year":"2025","journal-title":"Endocr Pract"},{"issue":"3","key":"2026051219561531200_bnaf042-B217","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1210\/clinem\/dgz023","article-title":"Efficacy and safety of first-and second-line drugs to prevent glucocorticoid-induced fractures","volume":"105","author":"Ding","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026051219561531200_bnaf042-B218","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026051219561531200_bnaf042-B219","doi-asserted-by":"crossref","first-page":"e220313","DOI":"10.20945\/2359-4292-2022-0313","article-title":"The risk of COVID-19 in Cushing's disease is independently related to disease activity (hypercortisolism) and obesity","volume":"68","author":"Mascarenhas-Nakano","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"2026051219561531200_bnaf042-B220","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","article-title":"Mortality in Cushing's syndrome: declining over 2 decades but remaining higher than the general population","volume":"192","author":"Akirov","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B221","doi-asserted-by":"crossref","first-page":"bvac045","DOI":"10.1210\/jendso\/bvac045","article-title":"Increased mortality persists after treatment of Cushing's disease: a matched Nationwide Cohort Study","volume":"6","author":"Bengtsson","year":"2022","journal-title":"J Endocr Soc"},{"issue":"9","key":"2026051219561531200_bnaf042-B222","doi-asserted-by":"crossref","first-page":"e240028","DOI":"10.1530\/ERC-24-0028","article-title":"Insights on epidemiology, morbidity and mortality of Cushing's disease in Northern Ireland","volume":"31","author":"Loughrey","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026051219561531200_bnaf042-B223","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11102-022-01258-4","article-title":"Cardiovascular health and mortality in Cushing's disease","volume":"25","author":"Coulden","year":"2022","journal-title":"Pituitary"},{"issue":"10","key":"2026051219561531200_bnaf042-B224","doi-asserted-by":"crossref","first-page":"E4232","DOI":"10.1210\/clinem\/dgac341","article-title":"Cushing mortality in remission: not out of the woods","volume":"107","author":"Kelsall","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026051219561531200_bnaf042-B225","doi-asserted-by":"crossref","first-page":"e13113","DOI":"10.1111\/jne.13113","article-title":"Long-term morbidity and mortality in patients with Cushing's syndrome","volume":"34","author":"Braun","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"2026051219561531200_bnaf042-B226","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1210\/clinem\/dgab058","article-title":"Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality","volume":"106","author":"Schernthaner-Reiter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026051219561531200_bnaf042-B227","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11102-023-01343-2","article-title":"Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre","volume":"26","author":"Mondin","year":"2023","journal-title":"Pituitary"},{"issue":"8","key":"2026051219561531200_bnaf042-B228","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","article-title":"The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality","volume":"107","author":"Limumpornpetch","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051219561531200_bnaf042-B229","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s12020-024-04073-y","article-title":"Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study","volume":"87","author":"Toma","year":"2025","journal-title":"Endocrine"},{"issue":"1","key":"2026051219561531200_bnaf042-B230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ejendo\/lvae069","article-title":"Long-term outcomes in patients with Cushing's disease vs nonfunctioning pituitary adenoma after pituitary surgery: an active-comparator cohort study","volume":"191","author":"Germann","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B231","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1093\/ejendo\/lvaf114","article-title":"Survival probabilities in patients with ectopic Cushing's syndrome\u2014a systematic review and a single-arm meta-analysis","volume":"192","author":"Piasecka","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026051219561531200_bnaf042-B232","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00423-022-02568-8","article-title":"Differences in morbidity and mortality between unilateral adrenalectomy for adrenal Cushing's syndrome and bilateral adrenalectomy for therapy refractory extra-adrenal Cushing's syndrome","volume":"407","author":"Reibetanz","year":"2022","journal-title":"Langenbeck's Arch Surg"},{"issue":"7","key":"2026051219561531200_bnaf042-B233","doi-asserted-by":"crossref","first-page":"e250059","DOI":"10.1530\/ERC-25-0059","article-title":"Predictors of cancer in patients with endogenous Cushing's syndrome","volume":"32","author":"Rudman","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026051219561531200_bnaf042-B234","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/EJE-18-0694","article-title":"Should we avoid using ketoconazole in patients with severe Cushing's syndrome and increased levels of liver enzymes?","volume":"179","author":"Ollivier","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026051219561531200_bnaf042-B235","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40265-016-0539-6","article-title":"Therapeutic strategies for the treatment of severe Cushing's syndrome","volume":"76","author":"Alexandraki","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"2026051219561531200_bnaf042-B236","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/17446651.2016.1123615","article-title":"Current strategies for the treatment of severe Cushing's syndrome","volume":"11","author":"Alexandraki","year":"2016","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026051219561531200_bnaf042-B237","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1440-1681.1991.tb01492.x","article-title":"Ketoconazole and plasma and urine steroid levels in Cushing's disease","volume":"18","author":"Mortimer","year":"1991","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"2026051219561531200_bnaf042-B238","doi-asserted-by":"crossref","first-page":"luaf091","DOI":"10.1210\/jcemcr\/luaf091","article-title":"Prolonged adrenal insufficiency after failed cryoablation and osilodrostat for Cushing syndrome in nodular adrenal disease","volume":"3","author":"Veloski","year":"2025","journal-title":"JCEM Case Rep"},{"issue":"6","key":"2026051219561531200_bnaf042-B239","doi-asserted-by":"crossref","first-page":"luae088","DOI":"10.1210\/jcemcr\/luae088","article-title":"Prolonged adrenal insufficiency after osilodrostat exposure with eventual recovery of adrenal function","volume":"2","author":"Tejani","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"6","key":"2026051219561531200_bnaf042-B240","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1093\/ejendo\/lvad060","article-title":"Prolonged adrenocortical blockade following discontinuation of Osilodrostat","volume":"188","author":"Poirier","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026051219561531200_bnaf042-B241","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1093\/ejendo\/lvad167","article-title":"Prolonged adrenal insufficiency following discontinuation of Osilodrostat treatment for intense hypercortisolism","volume":"190","author":"Ferriere","year":"2024","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnaf042\/66264465\/bnaf042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/47\/3\/301\/66264465\/bnaf042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/47\/3\/301\/66264465\/bnaf042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:56:54Z","timestamp":1778630214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/47\/3\/301\/8414095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":241,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,5,13]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnaf042","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,5]]}}}